A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis: Comment on the article by Maksymowych et al

A six-month randomized, controlled, doub

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis

✍ Walter P. Maksymowych; Gian S. Jhangri; Avril A. Fitzgerald; Sharon LeClercq; Pe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## Objective To determine the safety and efficacy of intravenous (IV) pamidronate treatment in ankylosing spondylitis (AS) patients who have had a suboptimal response to nonsteroidal antiinflammatory drugs (NSAIDs). ## Methods Pamidronate at 60 mg was compared with pamidronate at 10